<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00521976</url>
  </required_header>
  <id_info>
    <org_study_id>NSD9253</org_study_id>
    <nct_id>NCT00521976</nct_id>
  </id_info>
  <brief_title>Risk Markers in the Acute Coronary Syndromes</brief_title>
  <acronym>RACS</acronym>
  <official_title>An Investigation of Activated Factor XII (Fxlla) as a Prognostic Marker.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helse Vest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Axis-Shield, Dundee, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helse Stavanger HF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of this trial is to assess the long-term prognostic value of different types of
      Factor XIIa in an unselected, single center series of 871 chest pain patients admitted to the
      emergency unit, employing blood samples collected at admission.

      The second purpose of this study is to assess the incremental prognostic value of B-type
      natriuretic peptide (BNP) and high-sensitive C-reactive protein (hsCRP).

      A third purpose of this study is to evaluate the prognostic impact of the Omega-3 Index which
      is a measure of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) relative to other
      fatty acids in the erythrocyte membrane.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND Cardiac troponins are sensitive markers for myocardial injury in ACS and even a
      minor elevation of cardiac troponins is associated with an increased risk for future adverse
      coronary events. However, a detectable troponin release occurs only in a part of patients
      admitted with ACS. The clinical outcomes and further prognosis of patients with ACS with
      absent TnT release vary widely, and the identification of potential high-risk patients with
      troponin negative ACS still remains a major problem in clinical routine. Therefore, the aim
      of this study is focused on identifying new biomarkers for risk stratification.

      Activated Factor XII: Activated Factor XII leads to contact activation and a number of
      pathophysiological processes, including hypotension, inflammation, thrombosis and
      fibrinolysis, are affected by contact activation following the activation of XIIa. Several
      studies have demonstrated a relation between XIIa and coronary artery heart disease (CAD)
      (1,2,3,4) and that XIIa levels post MI predict recurrent coronary occlusive events and play a
      role as an independent risk marker in these patients (5).

      However, the detailed mechanisms of XIIa`s actions in CAD still remain uncertain although
      recent findings in animal studies using FXII deficient mice indicate that Factor XII is
      essential for arterial thrombus formation (6).

      Recent research indicates that in-vivo XIIa exists in multiple types and that in-vivo XIIa
      can exist in the circulation complexed to a variety of other proteins (7). To date, no data
      exist on the prognostic value of specific in-vivo types of XIIa on outcome in patients with
      chest pain and/or ACS.

      B-type natriuretic peptide: B-type natriuretic peptide (BNP) is a counter-regulatory peptide
      hormone predominantly synthesized in the ventricular myocardium. BNP is released into the
      circulation in response to ventricular dilatation and pressure overload, and reflects
      ventricular wall stress and tissue hypoxia rather than cell injury per se (8, 9). It is a
      well known marker of left ventricular dysfunction and heart failure (HF), and it provides
      prognostic information beyond and above left ventricular ejection fraction (LVEF) in patients
      with an acute coronary syndrome (ACS) (10). This marker of neurohormonal activation and
      inflammation plays a pivotal role across the spectrum of ACS, including patients with
      ST-elevation myocardial infarction (MI) and non ST-elevation ACS (NSTE-ACS). Previous studies
      have demonstrated that BNP measured in the first days after the onset of symptoms
      independently predicts mortality, HF, and new MI in this patient population. Elevated
      natriuretic peptides at presentation have been shown to identify patients with ACS who are at
      higher risk of death and HF, and it adds information to that provided by the troponins
      (11-13). However, in a low-risk population the association between elevated BNP and survival
      is attenuated when adjustment is made for echocardiographic variables (in addition to
      clinical covariates), as shown by Wang and colleagues. In addition, they did not find any
      association between baseline BNP and the risk of coronary heart disease (CHD) (14).

      High-sensitive C-reactive protein (hsCRP): C-reactive protein (CRP) is an acute-phase
      reactant that is produced in response to acute injury, infection or other inflammation
      stimuli. It is a marker for underlying systemic inflammation and plays an important role in
      the initiation and propagation of atherosclerosis and ultimately to plaque rupture and the
      ensuing thrombotic complication (15) Elevated levels of CRP were first reported in patients
      hospitalized with NSTE-ACS in the early 1990s (16, 17). Through the use of appropriate
      high-sensitive assays, it has been possible to investigate the relationship between plasma
      CRP levels that previously were considered to be normal and cardiovascular disease (CVD).
      Nevertheless, it is still under debate which markers should be preferred for risk prediction
      (18, 19). It has been suggested that the combined evaluation of BNP and CRP may yield
      incremental prognostic information in the risk stratification of patients with ACS (20), and
      their combined use has been shown to improve long-term risk prediction of mortality in
      patients with stable CHD (21). To our knowledge, there are limited data available that
      directly compare these two markers in a prospective manner in an unselected patient
      population presenting to the emergency department (ED) with chest pain. In addition, their
      role in risk stratification in patients with ACS is still under evaluation, and therefore
      additional investigations are necessary.

      Omega- 3 Index: The value of the Omega-3 Index as a prognostic marker in the acute coronary
      syndromes is still under investigation.

      STUDY DESIGN This prospective single center observational non-invasive trial includes 871 men
      and women admitted with chest pain and potential ACS at the Stavanger University Hospital
      between November 2002 and October 2003. Blood samples were collected immediately following
      admission. Patients were stratified according to peak troponin T (TnT) release following
      admission; i.e. 1) patients with an admission TnT exceeding 0.05 ng/mL, and 2) patients with
      a peak TnT level of 0.05 ng/mL or lower.

      Assessment of a history of previous MI, angina pectoris (AP), congestive heart failure (CHF),
      diabetes mellitus and arterial hypertension was based on hospital records and personal
      interview. Electrocardiographic findings at admission were classified according to the
      presence of ST segment changes.

      Written informed consent was obtained from all patients. Survival status, date and cause of
      death and clinical data were obtained by telephone interview and hospital journal reports at
      4 predefined time points (30 days, 6, 12 and 24 months) during the two year follow-up period.
      In case of incapacity to provide information, the general practitioner or nursery home were
      contacted for relevant data. Hospital journals were searched for confirmation of reported
      data.

      Primary Outcome Measures:

        -  During follow-up

        -  All cause death

        -  Non-fatal acute myocardial infarction (MI)

        -  Combined endpoint of all cause death or non-fatal acute MI

        -  Combined endpoint of cardiovascular death or non-fatal acute MI

      Secondary Outcome Measures:

        -  During follow-up

        -  Acute hospitalizations for angina

        -  Myocardial revascularization

      STEERING COMMITTEE

        -  Professor Dennis WT Nilsen MD PhD, Department of Heart Disease, Stavanger University
           Hospital

        -  Heidi Grundt MD PhD Department of Medicine, Stavanger University Hospital

        -  Ã˜yvind Hetland MD PhD, Department of Clinical Chemistry, Stavanger University Hospital

        -  Ole Kristensen MD, Department of Clinical Chemistry, Stavanger University Hospital

      BIOLOGICAL SAMPLE OWNERSHIP. The biological samples are owned by Stavanger University
      Hospital and their use for scientific purposes is administered by the Steering Committee.

      DATA OWNERSHIP AND PUBLICATION OF RESULTS. The RACS Steering Committee has the ownership of
      all data registered in the RACS database, and any use of these data including the preparation
      and publication of scientific reports must be approved by the Steering Committee. Scientific
      articles will be published by RACS investigators or by authors mentioned by name. The author
      sequence should be approved by the Steering Committee and based upon contribution. Incentives
      to involve articles as part of a doctoral thesis should be encouraged. All collaborators in
      the study will be mentioned by name in an Appendix section of the main article from the
      study. The results will be published in peer-reviewed scientific journals and in magazines
      for the general public.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total Mortality.</measure>
    <time_frame>24 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent Troponin-T (TnT) Positive Events</measure>
    <time_frame>24 months.</time_frame>
    <description>Recurrent Troponin-T (TnT) positive events; Symptoms of coronary ischemia associated with TnT &gt;0.05 ng/mL with a pattern of gradual rise and fall in TnT</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">871</enrollment>
  <condition>Chest Pain</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Unstable Angina Pectoris</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Chest pain</arm_group_label>
    <description>Men and women admitted with chest pain and suspected acute coronary syndrome (ACS).</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, Citrated plasma, EDTA-plasma and packed red blood cells are kept in suitable aliquots
      at -80 degrees Celcius.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        871 men and women admitted with chest pain and potential acute cornary syndrome (ACS) at
        the Stavanger University Hospital between November 2002 and October 2003.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults &gt; 18 years able to give informed consent

          -  a history of chest pain or other symptoms suggestive of an ACS leading to admission at
             the emergency unit

        Exclusion Criteria:

          -  &lt; 18 years of age

          -  Unwillingness or incapacity to provide informed consent

          -  Prior admission resulting in inclusion in the present study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis WT Nilsen, MD PhD FESC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stavanger University Hospital, Dept. of Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <state>Rogaland</state>
        <zip>4068</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>http://www.etikkom.no/REK</url>
    <description>Regional Ethics Committee</description>
  </link>
  <link>
    <url>http://www.nsd.uib.no</url>
    <description>Norwegian Social Science Data Services</description>
  </link>
  <reference>
    <citation>Miller GJ, Esnouf MP, Burgess AI, Cooper JA, Mitchell JP. Risk of coronary heart disease and activation of factor XII in middle-aged men. Arterioscler Thromb Vasc Biol. 1997 Oct;17(10):2103-6.</citation>
    <PMID>9351378</PMID>
  </reference>
  <reference>
    <citation>Zito F, Drummond F, Bujac SR, Esnouf MP, Morrissey JH, Humphries SE, Miller GJ. Epidemiological and genetic associations of activated factor XII concentration with factor VII activity, fibrinopeptide A concentration, and risk of coronary heart disease in men. Circulation. 2000 Oct 24;102(17):2058-62.</citation>
    <PMID>11044420</PMID>
  </reference>
  <reference>
    <citation>Cooper JA, Miller GJ, Bauer KA, Morrissey JH, Meade TW, Howarth DJ, Barzegar S, Mitchell JP, Rosenberg RD. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation. 2000 Dec 5;102(23):2816-22.</citation>
    <PMID>11104738</PMID>
  </reference>
  <reference>
    <citation>Kohler HP, Carter AM, Stickland MH, Grant PJ. Levels of activated FXII in survivors of myocardial infarction--association with circulating risk factors and extent of coronary artery disease. Thromb Haemost. 1998 Jan;79(1):14-8.</citation>
    <PMID>9459314</PMID>
  </reference>
  <reference>
    <citation>Pritchard D, Polwart R. In-vivo, activated factor XII exists in multiple forms, but predominantly as a 53 kD Species. J Thromb and Haemost 2005; Suppl.1; ISSN 1740-3340.</citation>
  </reference>
  <reference>
    <citation>Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 1998 May;135(5 Pt 1):825-32.</citation>
    <PMID>9588412</PMID>
  </reference>
  <reference>
    <citation>Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, Nishino K, Yoshimasa T, Nakao K. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an &quot;emergency&quot; cardiac hormone against ventricular overload. J Clin Invest. 1995 Sep;96(3):1280-7.</citation>
    <PMID>7657802</PMID>
  </reference>
  <reference>
    <citation>Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, Frampton C, Turner J, Crozier IG, Yandle TG. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation. 2003 Jun 10;107(22):2786-92. Epub 2003 May 27.</citation>
    <PMID>12771003</PMID>
  </reference>
  <reference>
    <citation>de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001 Oct 4;345(14):1014-21.</citation>
    <PMID>11586953</PMID>
  </reference>
  <reference>
    <citation>Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Gibson CM, Cannon CP, Braunwald E. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol. 2003 Apr 16;41(8):1264-72. Erratum in: J Am Coll Cardiol. 2003 May 21;41(10):1852.</citation>
    <PMID>12706919</PMID>
  </reference>
  <reference>
    <citation>Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, Hartford M, Caidahl K. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002 Dec 3;106(23):2913-8.</citation>
    <PMID>12460871</PMID>
  </reference>
  <reference>
    <citation>Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004 Feb 12;350(7):655-63.</citation>
    <PMID>14960742</PMID>
  </reference>
  <reference>
    <citation>Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999 Jan 14;340(2):115-26. Review.</citation>
    <PMID>9887164</PMID>
  </reference>
  <reference>
    <citation>Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994 Aug 18;331(7):417-24.</citation>
    <PMID>7880233</PMID>
  </reference>
  <reference>
    <citation>Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in &quot;active&quot; coronary artery disease. Am J Cardiol. 1990 Jan 15;65(3):168-72.</citation>
    <PMID>2296885</PMID>
  </reference>
  <reference>
    <citation>de Lemos JA. The latest and greatest new biomarkers: which ones should we measure for risk prediction in our practice? Arch Intern Med. 2006 Dec 11-25;166(22):2428-30. Erratum in: Arch Intern Med. 2007 Feb 26;167(4):353.</citation>
    <PMID>17159006</PMID>
  </reference>
  <reference>
    <citation>Rothenbacher D, Koenig W, Brenner H. Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease. Arch Intern Med. 2006 Dec 11-25;166(22):2455-60.</citation>
    <PMID>17159010</PMID>
  </reference>
  <reference>
    <citation>Kim H, Yang DH, Park Y, Han J, Lee H, Kang H, Park HS, Cho Y, Chae SC, Jun JE, Park WH. Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome. Circ J. 2006 Nov;70(11):1379-84.</citation>
    <PMID>17062957</PMID>
  </reference>
  <reference>
    <citation>Ndrepepa G, Kastrati A, Braun S, Mehilli J, NiemÃ¶ller K, von Beckerath N, von Beckerath O, Vogt W, SchÃ¶mig A. N-terminal probrain natriuretic peptide and C-reactive protein in stable coronary heart disease. Am J Med. 2006 Apr;119(4):355.e1-8.</citation>
    <PMID>16564781</PMID>
  </reference>
  <reference>
    <citation>Harris WS, Sands SA, Windsor SL, Ali HA, Stevens TL, Magalski A, Porter CB, Borkon AM. Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation. Circulation. 2004 Sep 21;110(12):1645-9. Epub 2004 Sep 7. Erratum in: Circulation. 2004 Nov 9;110(19):3156.</citation>
    <PMID>15353491</PMID>
  </reference>
  <results_reference>
    <citation>PÃ¶nitz V, Pritchard D, Grundt H, Nilsen DW. Specific types of activated Factor XII increase following thrombolytic therapy with tenecteplase. J Thromb Thrombolysis. 2006 Dec;22(3):199-203.</citation>
    <PMID>17111198</PMID>
  </results_reference>
  <results_reference>
    <citation>PÃ¶nitz V, Pritchard D, Grundt H, Mehus MB, Nilsen DW. Changes of plasma activated Factor XII type A (XIIaA) concentrations following percutaneous coronary intervention (PCI). J Thromb Thrombolysis. 2007 Oct;24(2):131-5. Epub 2007 May 11.</citation>
    <PMID>17492403</PMID>
  </results_reference>
  <results_reference>
    <citation>BrÃ¼gger-Andersen T, Hetland Ã˜, PÃ¶nitz V, Grundt H, Nilsen DW. The effect of primary percutaneous coronary intervention as compared to tenecteplase on myeloperoxidase, pregnancy-associated plasma protein A, soluble fibrin and D-dimer in acute myocardial infarction. Thromb Res. 2007;119(4):415-21. Epub 2006 May 2.</citation>
    <PMID>16650886</PMID>
  </results_reference>
  <results_reference>
    <citation>PÃ¶nitz V, BrÃ¼gger-Andersen T, Pritchard D, Grundt H, Staines H, Nilsen DW; RACS Study Group. Activated factor XII type A predicts long-term mortality in patients admitted with chest pain. J Thromb Haemost. 2009 Feb;7(2):277-87. doi: 10.1111/j.1538-7836.2008.03248.x. Epub 2008 Dec 1.</citation>
    <PMID>19054318</PMID>
  </results_reference>
  <results_reference>
    <citation>BrÃ¼gger-Andersen T, PÃ¶nitz V, Staines H, Grundt H, Hetland Ã˜, Nilsen DW. The prognostic utility of D-dimer and fibrin monomer at long-term follow-up after hospitalization with coronary chest pain. Blood Coagul Fibrinolysis. 2008 Oct;19(7):701-7. doi: 10.1097/MBC.0b013e32830b1512.</citation>
    <PMID>18832914</PMID>
  </results_reference>
  <results_reference>
    <citation>BrÃ¼gger-Andersen T, PÃ¶nitz V, Staines H, Pritchard D, Grundt H, Nilsen DW. B-type natriuretic peptide is a long-term predictor of all-cause mortality, whereas high-sensitive C-reactive protein predicts recurrent short-term troponin T positive cardiac events in chest pain patients: a prognostic study. BMC Cardiovasc Disord. 2008 Nov 25;8:34. doi: 10.1186/1471-2261-8-34.</citation>
    <PMID>19032759</PMID>
  </results_reference>
  <results_reference>
    <citation>AarsetÃ¸y H, PÃ¶nitz V, Nilsen OB, Grundt H, Harris WS, Nilsen DW. Low levels of cellular omega-3 increase the risk of ventricular fibrillation during the acute ischaemic phase of a myocardial infarction. Resuscitation. 2008 Sep;78(3):258-64. doi: 10.1016/j.resuscitation.2008.04.007. Epub 2008 Jun 16.</citation>
    <PMID>18556107</PMID>
  </results_reference>
  <results_reference>
    <citation>Aarsetoey H, PÃ¶nitz V, Grundt H, Staines H, Harris WS, Nilsen DW. (n-3) Fatty acid content of red blood cells does not predict risk of future cardiovascular events following an acute coronary syndrome. J Nutr. 2009 Mar;139(3):507-13. doi: 10.3945/jn.108.096446. Epub 2009 Jan 21.</citation>
    <PMID>19158216</PMID>
  </results_reference>
  <results_reference>
    <citation>Naesgaard PA, PÃ¶nitz V, Aarsetoey H, BrÃ¼gger-Andersen T, Grundt H, Harris WS, Staines H, Nilsen DW. Prognostic utility of vitamin D in acute coronary syndrome patients in coastal Norway. Dis Markers. 2015;2015:283178. doi: 10.1155/2015/283178. Epub 2015 Feb 5.</citation>
    <PMID>25722531</PMID>
  </results_reference>
  <results_reference>
    <citation>Mjelva OR, BrÃ¼gger-Andersen T, PÃ¶nitz V, Grundt H, Kontny F, Staines H, Nilsen DW. Long-term prognostic utility of PAPP-A and calprotectin in suspected acute coronary syndrome. Scand Cardiovasc J. 2013 Apr;47(2):88-97. doi: 10.3109/14017431.2013.764571. Epub 2013 Feb 13.</citation>
    <PMID>23406538</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2007</study_first_submitted>
  <study_first_submitted_qc>August 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2007</study_first_posted>
  <results_first_submitted>January 9, 2009</results_first_submitted>
  <results_first_submitted_qc>June 22, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 11, 2009</results_first_posted>
  <last_update_submitted>May 19, 2015</last_update_submitted>
  <last_update_submitted_qc>May 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Risk assessment</keyword>
  <keyword>Chest pain</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Acute coronary syndromes</keyword>
  <keyword>Factor XIIa</keyword>
  <keyword>B-type natriuretic peptide (BNP)</keyword>
  <keyword>high-sensitive C-reactive protein (hsCRP)</keyword>
  <keyword>Omega-3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Chest Pain</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Consecutive recruitment at Stavanger University Hospital.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>Men and women admitted with chest pain and a suspicious acute coronary syndrome (ACS)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="871"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="871"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Men and women admitted with chest pain and a suspicious acute coronary syndrome (ACS)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="871"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.6" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Mortality.</title>
        <time_frame>24 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Men and women admitted with chest pain and a suspicious acute coronary syndrome (ACS)</description>
          </group>
        </group_list>
        <measure>
          <title>Total Mortality.</title>
          <units>Participants.</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="871"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrent Troponin-T (TnT) Positive Events</title>
        <description>Recurrent Troponin-T (TnT) positive events; Symptoms of coronary ischemia associated with TnT &gt;0.05 ng/mL with a pattern of gradual rise and fall in TnT</description>
        <time_frame>24 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Men and women admitted with chest pain and a suspicious acute coronary syndrome (ACS)</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrent Troponin-T (TnT) Positive Events</title>
          <description>Recurrent Troponin-T (TnT) positive events; Symptoms of coronary ischemia associated with TnT &gt;0.05 ng/mL with a pattern of gradual rise and fall in TnT</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="871"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Men and women admitted with chest pain and a suspicious acute coronary syndrome (ACS)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="871"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="871"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dennis W.T. Nilsen MD PhD FESC FAHA</name_or_title>
      <organization>Stavanger University Hospital</organization>
      <phone>+4705151 ext 9455</phone>
      <email>nide@sus.no</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

